A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2070 Injection in Healthy Subjects
Latest Information Update: 03 Dec 2025
At a glance
- Drugs SYH 2070 (Primary)
- Indications Hyperglycaemia
- Focus Adverse reactions
- Sponsors CSPC Zhongnuo Pharmaceutical
Most Recent Events
- 03 Dec 2025 New trial record